Journals / TSK Koruyucu Hekimlik Bülteni / 2006 / Cilt: 5 - Sayı: 2

Melatonin: Toplum sağlığını geliştirmek için potansiyel kullanımı

Melatonin: Potential utility for improving public health

Pages
131–158
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Collectively, these data suggest supplementation with melatonin, whose endogenous levels decrease with age, may improve the quality of life in the aged and, as a consequence, be beneficial for public health generally.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This review summarizes the beneficial actions of melatonin in various experimental conditions/diseases and identifies where the use of melatonin may be helpful in improving public health.
📊
Key Findings & Data:The nightly use of melatonin supplements by humans often improves their sleep and helps correct the circadian dyssynchronization associated with “jet lag”.
💡
Conclusion & Impact:Collectively, these data suggest supplementation with melatonin, whose endogenous levels decrease with age, may improve the quality of life in the aged and, as a consequence, be beneficial for public health generally.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Antioksidanlar · Melatonin · Halk sağlığı

Abstract

This review summarizes the beneficial actions of melatonin in various experimental conditions/diseases and identifies where the use of melatonin may be helpful in improving public health. The nightly use of melatonin supplements by humans often improves their sleep and helps correct the circadian dyssynchronization associated with “jet lag”. Additionally, melatonin has been found effective in curtailing the growth of a variety of experimental cancers. Mechanistically, this is achieved by melatonin’s ability to limit fatty acid uptake, especially linoleic acid, by tumor cells. Fatty acids are growth factors for many tumors. Additionally, melatonin inhibits the elevated telomerase activity of tumor cells thus making them more fragile and vulnerable to chemotherapies. Melatonin also may inhibit angiogenesis in tumors by suppressing endothelin-1 production and the indole interferes with the stimulatory action of steroids on hormone-responsive tumors. As an ubiquitously-acting antioxidant, melatonin reduces cardiac damage during ischemia/reperfusion (I/R) injury (heart attack) and during I/R to the brain (stroke). Melatonin also limits the toxicity of amyloid beta peptide and of neurofibrillary tangles, two of the cardinal signs of Alzheimer’s disease. Collectively, these data suggest supplementation with melatonin, whose endogenous levels decrease with age, may improve the quality of life in the aged and, as a consequence, be beneficial for public health generally.

Özet

Bu derleme melatoninin çeşitli deneysel durum/hastalıktaki faydalı etkilerini özetlemekte ve melatoninin toplum sağlığını geliştirmede faydalı olabilecek kullanım alanlarını belirlemektedir. Melatoninin gecelik kullanımı sıklıkla uyku kalitesini arttırmakta ve “jet lag”la ilişkili sirkadiyan senkronizasyon bozukluğunu düzeltmeye yardımcı olmaktadır. İlave olarak melatoninin çeşitli deneysel kanserlerin büyümesini yavaşlatmada etkili olduğu bulunmuştur. Bu; melatoninin tümör hücreleri tarafından yağ asitlerini, özellikle de linoleik asitin, alımını sınırlamasıyla başarılmaktadır. Yağ asitleri bir çok tümör için büyüme faktörüdür. Buna ilave olarak, melatonin tümör hücrelerinin artmış telomeraz aktivitelerini inhibe etmekte ve dolayısı ile bu hücreleri daha frajil ve kemoterapilere karşı daha duyarlı hale getirmektedir. Melatonin aynı zamanda endotelin-1 üretimini ve hormon-bağımlı tümörlerdeki steroidlerin stimülatuvar etkilerini engelleyen indolü baskılayarak tümörlerdeki anjiogenezisi inhibe edebilir. Eşsiz bir antioksidan olarak melatonin, iskemi/reperfüzyon (I/R) bozukluğunda (kalp krizi) meydana gelen kardiyak hasarı ve beyin I/R bozukluğundaki (inme) beyin hasarını azaltır. Melatonin ayrıca Alzheimer hastalığının iki temel bulgusu olan amiloid  peptid ve nörofibrular düğüm toksititesini sınırlar. Kısacası bu veriler, endojen düzeyleri yaşla azalan, melatonin takviyesinin yaşlılıkta yaşam kalitesini arttırabileceğini ve sonuçta tüm toplum sağlığı için genel olarak faydalı olabileceğini desteklemektedir.

🔖

Cite This Article

REITER, R. J., GÜLTEKİN, F., FLORES, L. J., TERRON, M. P., TAN, D. (2006). Melatonin: Toplum sağlığını geliştirmek için potansiyel kullanımı. TSK Koruyucu Hekimlik Bülteni, Cilt: 5 - Sayı: 2, 131–158. https://ajindex.com/articles/132235

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Pappolla MA, Chyan YJ, Poeggeler B, Frangione R, Wilson G et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm. 2000; 107:203-31
  2. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S et al. Effects of melatonin treatment on septic newborns. Pediatr Res. 2001; 50:756-60
  3. Herrera J, Nava M, Romero F, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis. 2001; 37:750-7
  4. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics Med Chem 2002; 2:113-33
  5. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer 2002; 10:110-6
  6. Todisco M, Casaccia P, Rossi N. Severe bleeding symptom’s in refractory idiopathic thrombocytopenia purpura: a case successfully treated with melatonin. Am J Therap. 2003; 10:135-6
  7. Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chuirazzi P et al. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm infants. Am J Perinotol. 2004; 21:209-16
  8. Reiter RJ, Tan DX, Pappaolla MA. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann NY Acad Sci. 2004; 1035: 179-86
  9. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005; 6:459-66
  10. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: Its beneficial actions in experimental models of stroke. Exp Biol Med. 2005; 230:104-17
  11. Reiter RJ. The pineal and its hormones in the control of reproduction in mammals. Endocr Rev. 1980; 1:109-31
  12. Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol. 1999; 460:425-34
  13. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Golen vein blood recirculating through the choroid plexus. Endocrinology. 1999; 140-4399-405
  14. Reiter RJ. Melatonin: the chemical expression of darkness. Molec Cell Endocrinol. 1991; 79:C153-9
  15. Pang SF, Allen AE. Extra-pineal melatonin in the retina: its regulation and physiological function. Pineal Res Rev. 1986; 4:55-96
  16. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: secur